Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) EPS (Weighted Average and Diluted) (2016 - 2025)

Plus Therapeutics has reported EPS (Weighted Average and Diluted) over the past 11 years, most recently at -$0.07 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 89.04% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.24 through Dec 2025, up 50.4% year-over-year, with the annual reading at -$0.29 for FY2025, 87.61% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.07 for Q4 2025 at Plus Therapeutics, down from -$0.04 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.01 in Q2 2025 and troughed at -$3.56 in Q2 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.68 (2023), against an average of -$0.98.
  • Year-over-year, EPS (Weighted Average and Diluted) plummeted 1324.0% in 2022 and then surged 98.59% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.28 in 2021, then tumbled by 742.86% to -$2.36 in 2022, then soared by 70.34% to -$0.7 in 2023, then rose by 4.29% to -$0.67 in 2024, then soared by 89.04% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's EPS (Weighted Average and Diluted) are -$0.07 (Q4 2025), -$0.04 (Q3 2025), and -$0.01 (Q2 2025).